drugset

drugset / Trial / NCT00239291

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

NCT00239291 ↗

Phase 1/2 Completed 42 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer

Timeline

Start: 2003-01
Primary completion: —
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefitinib	Small molecule	250 mg	—

Indications